Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

Pegfilgrastim is indicated for reducing the duration of neutropenia and incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy. Here, safety and efficacy of MYL-1401H, a proposed pegfilgrastim biosimilar, were investigated as prophylaxis for chemotherapy-induced neutropenia. T...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Hematol
Päätekijät: Waller, Cornelius F., Ranganna, Gopinath M., Pennella, Eduardo J., Blakeley, Christopher, Bronchud, Miguel H., Mattano Jr, Leonard A., Berzoy, Oleksandr, Voitko, Nataliia, Shparyk, Yaroslav, Lytvyn, Iryna, Rusyn, Andriy, Popov, Vasil, Láng, István, Beckmann, Katrin, Sharma, Rajiv, Baczkowski, Mark, Kothekar, Mudgal, Barve, Abhijit
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2019
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469669/
https://ncbi.nlm.nih.gov/pubmed/30824956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-019-03639-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia